Investigating the effect of Tdcs on metacognitive therapy in the treatment of major depressed people

Psychotherapy plus: augmentation of metacognitive therapy with prefrontal transcranial direct current stimulation (tDCS) on depressive symptoms, rumination, and brain waves pattern based on quantitative analysis of the electroencephalogram (QEEG) in individuals with major depressive disorder- sham-controlled randomized double-blind study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190812044515N1

Enrollment

Registered

2023-08-28

Start date

2022-11-22

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression. Major depressive disorder, single episode

Interventions

Intervention 1: The first intervention group: metacognitive therapy + Active-tDCS, in the above intervention, after the session entered the main part, i.e. the challenge with beliefs, real tDCS with a

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Not having a history of participating in a metacognitive psychotherapy program. Not having a history of epilepsy or convulsions. Not having a history of shock therapy (ECT). Having a score above 20 in the Beck depression questionnaire. Not having acute suicidality to participate in treatment sessions. Positive safety screening to perform tDCS.

Exclusion criteria

Exclusion criteria: Substance abuse or dependence in the last 6 months (excluding nicotine, with current or past nicotine use) Psychotic disorders (lifelong) including schizoaffective disorders or depressive episodes with psychotic symptoms (lifelong) Bipolar disorders (types I and II) Neurological disorders, such as stroke in the last 2 years, epileptic attacks (for life), epilepsy, dementia, Parkinson's, Huntington's, multiple sclerosis, as well as any other neurological disease that leads to increased intracranial pressure or increased risk of epileptic seizures Not having a current risk of suicide, based on the researcher's personal assessment

Design outcomes

Primary

Measure	Time frame
Depression score. Timepoint: Measurement of depression at the beginning of the study and 10 sessions after the intervention and 30 days after the last visit session. Method of measurement: Beck Depression Questionnaire and Nelen Hoeksma Rumination Questionnaire.	—

Secondary

Measure	Time frame
Rumination. Timepoint: At the beginning of the study and the last visit and 30 days after the last visit. Method of measurement: Nelen Hoeksma Rumination Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahnaz Nouhi

Islamic Azad University

psynut.sh@gmail.com0092332394530

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026